To evaluate the potential of B1.23.2 in anti-tumor immunity, NSG-IL15 mice were given the KLM-1 human pancreatic tumor, then engrafted with human CD3− cells, and monitored for tumor growth (Fig. 5f). Here, IL15 is linked to neoplasm.